Literature DB >> 9816311

Interleukin 10 production by human melanoma.

T Sato1, P McCue, K Masuoka, S Salwen, E C Lattime, M J Mastrangelo, D Berd.   

Abstract

Interleukin 10 (IL-10) has the physiological role of down-regulating cell-mediated immunity. We have recently reported that mRNA for IL-10 was present in most metastatic melanoma tissues. The purpose of this investigation was to determine whether melanoma metastases produce IL-10 protein. Single-cell suspensions were prepared by enzymatic dissociation of 28 lymph node metastases and 7 s.c. metastases and cryopreserved. Of these 35 samples, 30 produced IL-10 after a 24-h incubation (median, 125.1 pg/ml). IL-10 production was slightly diminished after 25 Gy irradiation but almost completely abrogated after modification with the hapten dinitrophenyl. After 7 or 14 days in tissue culture, melanoma cells continued to produce IL-10 but only at about 10% of the levels of freshly dissociated tissues. Moreover, of eight melanoma cell lines established from these cultures, only one produced IL-10 protein. To determine whether IL-10 was produced by melanoma cells or tumor-associated leukocytes, single-cell suspensions were fractionated with anti-CD45 antibody-conjugated magnetic beads. In four of five samples, IL-10 production was increased by depletion of leukocytes, suggesting that the primary source was the melanoma cells themselves. This was confirmed by immunohistochemical staining of cytospin preparations and frozen tissue sections. Finally, 10 of 55 patients with clinically evident metastases showed elevations of circulating IL-10; three patients who had been melanoma-free developed high serum IL-10 levels, concurrent with the appearance of distant metastases. These data indicate that production of IL-10 is characteristic of metastatic melanomas and raise the possibility that this cytokine allows tumors to avoid or to modulate immunological attack.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816311

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.

Authors:  Maja A Hofmann; Felix Kiecker; Ingeborg Küchler; Christian Kors; Uwe Trefzer
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-09       Impact factor: 4.553

2.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

Review 3.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

4.  Disseminated Kaposi's sarcoma in patients with HIV infection correlates to high serum levels of IL-10.

Authors:  Paula Renata Lima Machado; Kleber Juvenal Silva Farias; Julieta Genre; Carlo José Freire Oliveira; Paulo Marcos Matta Guedes; Benedito Antônio Lopes da Fonseca
Journal:  Viral Immunol       Date:  2014-07-15       Impact factor: 2.257

5.  Different levels of TGFbeta, IL-10, IFNgamma and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells.

Authors:  C A La Porta; R Comolli
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 6.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

7.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

8.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

9.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

Authors:  Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

10.  Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth.

Authors:  Aline Bolpetti; João S Silva; Luisa L Villa; Ana Paula Lepique
Journal:  BMC Immunol       Date:  2010-06-07       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.